423 related articles for article (PubMed ID: 31369717)
21. Nanoparticulate RNA delivery systems in cancer.
Sharma A; Jha NK; Dahiya K; Singh VK; Chaurasiya K; Jha AN; Jha SK; Mishra PC; Dholpuria S; Astya R; Nand P; Kumar A; Ruokolainen J; Kesari KK
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1271. PubMed ID: 32729987
[TBL] [Abstract][Full Text] [Related]
22. PAMAM Dendrimers as a Delivery System for Small Interfering RNA.
Kheiriabad S; Ghaffari M; Dolatabadi JEN; Hamblin MR
Methods Mol Biol; 2020; 2115():91-106. PubMed ID: 32006396
[TBL] [Abstract][Full Text] [Related]
23. Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy.
Mirzaei S; Gholami MH; Ang HL; Hashemi F; Zarrabi A; Zabolian A; Hushmandi K; Delfi M; Khan H; Ashrafizadeh M; Sethi G; Kumar AP
Cells; 2021 Nov; 10(12):. PubMed ID: 34943856
[TBL] [Abstract][Full Text] [Related]
24. Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents.
Zhao J; Feng SS
Nanomedicine (Lond); 2015 Jul; 10(14):2199-228. PubMed ID: 26214357
[TBL] [Abstract][Full Text] [Related]
25. Inorganic nanocarriers for siRNA delivery for cancer treatments.
Kandasamy G; Maity D
Biomed Mater; 2024 Jan; 19(2):. PubMed ID: 38181441
[TBL] [Abstract][Full Text] [Related]
26. Current advancements in self-assembling nanocarriers-based siRNA delivery for cancer therapy.
Kandasamy G; Maity D
Colloids Surf B Biointerfaces; 2023 Jan; 221():113002. PubMed ID: 36370645
[TBL] [Abstract][Full Text] [Related]
27. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
[TBL] [Abstract][Full Text] [Related]
28. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
Hatakeyama H; Wu SY; Mangala LS; Lopez-Berestein G; Sood AK
Methods Mol Biol; 2016; 1402():189-197. PubMed ID: 26721492
[TBL] [Abstract][Full Text] [Related]
29. Biomedical application of chitosan-based nanoscale delivery systems: Potential usefulness in siRNA delivery for cancer therapy.
Ashrafizadeh M; Delfi M; Hashemi F; Zabolian A; Saleki H; Bagherian M; Azami N; Farahani MV; Sharifzadeh SO; Hamzehlou S; Hushmandi K; Makvandi P; Zarrabi A; Hamblin MR; Varma RS
Carbohydr Polym; 2021 May; 260():117809. PubMed ID: 33712155
[TBL] [Abstract][Full Text] [Related]
30. Nanocarrier Mediated siRNA Delivery Targeting Stem Cell Differentiation.
Fernandes F; Kotharkar P; Chakravorty A; Kowshik M; Talukdar I
Curr Stem Cell Res Ther; 2020; 15(2):155-172. PubMed ID: 31789134
[TBL] [Abstract][Full Text] [Related]
31. Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach.
Mahmoodi Chalbatani G; Dana H; Gharagouzloo E; Grijalvo S; Eritja R; Logsdon CD; Memari F; Miri SR; Rad MR; Marmari V
Int J Nanomedicine; 2019; 14():3111-3128. PubMed ID: 31118626
[TBL] [Abstract][Full Text] [Related]
32. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in siRNA delivery for cancer therapy using smart nanocarriers.
Zhang P; An K; Duan X; Xu H; Li F; Xu F
Drug Discov Today; 2018 Apr; 23(4):900-911. PubMed ID: 29373841
[TBL] [Abstract][Full Text] [Related]
34. A biomimetic camouflaged metal organic framework for enhanced siRNA delivery in the tumor environment.
Tao T; Rehman SU; Xu S; Zhang J; Xia H; Guo Z; Li Z; Ma K; Wang J
J Mater Chem B; 2024 May; 12(17):4080-4096. PubMed ID: 38577851
[TBL] [Abstract][Full Text] [Related]
35. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
[TBL] [Abstract][Full Text] [Related]
36. Design, strategies, and therapeutics in nanoparticle-based siRNA delivery systems for breast cancer.
Yan C; Zhang J; Huang M; Xiao J; Li N; Wang T; Ling R
J Mater Chem B; 2023 Aug; 11(34):8096-8116. PubMed ID: 37551630
[TBL] [Abstract][Full Text] [Related]
37. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics.
Lorenzer C; Dirin M; Winkler AM; Baumann V; Winkler J
J Control Release; 2015 Apr; 203():1-15. PubMed ID: 25660205
[TBL] [Abstract][Full Text] [Related]
38. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
39. Delivery materials for siRNA therapeutics.
Kanasty R; Dorkin JR; Vegas A; Anderson D
Nat Mater; 2013 Nov; 12(11):967-77. PubMed ID: 24150415
[TBL] [Abstract][Full Text] [Related]
40. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
